BIOMAT Database Logo BIOMAT Database Logo

[Reactogenicity, toxicity and tolerance of reaferon in healthy volunteers]. 1988

V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina

In the clinical trial of reaferon, introduced intramuscularly and intravenously in different doses (2 X 10(6), 6 X 10(6) and 9 X 10(6) I. U. daily) for 3 days, various side effects were observed. Their intensity depended on the dose of the preparation and the route of administration. The most regular reaction was a rise in temperature, accompanied by slight weakness, headache, loss of appetite, slight dizziness, euphoria. All side effects were transient. No toxic or allergic reactions involving the organs and systems of the body were observed. Low doses of the preparation (2 X 10(6) I. U. daily) promoted an increase in the amount of lymphocytes in the peripheral blood, stimulated cellular immunity factors and contributed to the optimal functioning of the interferon systems. High doses (6 X 10(6) to 9 X 10(6) I. U. daily) had a pronounced immunosuppressing effect. On the whole, reaferon proved to be fairly tolerable.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
Plafibride tolerance trial in healthy volunteers.
January 1981, Arzneimittel-Forschung,
V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
Renal tolerance of fleroxacin in healthy volunteers.
October 1988, The Journal of antimicrobial chemotherapy,
V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
Pharmacokinetics and tolerance of fluconazole suppositories in healthy volunteers.
March 1993, Arzneimittel-Forschung,
V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
Ventilatory efficiency and exercise tolerance in 101 healthy volunteers.
April 1998, European journal of applied physiology and occupational physiology,
V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
Single dose pharmacokinetics and tolerance of pancopride in healthy volunteers.
February 1995, Arzneimittel-Forschung,
V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
October 1988, The Journal of antimicrobial chemotherapy,
V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.
September 1984, The Journal of antimicrobial chemotherapy,
V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
Medifoxamine: oral tolerance and pharmacokinetic study in healthy human volunteers.
January 1990, European journal of clinical pharmacology,
V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
Plafibride tolerance trial at increasing doses in healthy volunteers.
January 1981, Arzneimittel-Forschung,
V I Pokrovskiĭ, and A V Zmyzgova, and R T Murzabaeva, and T N Fomina, and N B Shalygina
Tolerance and pharmacokinetics of A515U, an acyclovir analogue, in healthy volunteers.
January 1984, European journal of clinical pharmacology,
Copied contents to your clipboard!